Simulations Plus

At Simulations Plus, our core mission – accelerating the development and delivery of better, safer, and more effective therapeutics – and the potential it offers for improving patients’ lives, and advancing and improving global health, has broad and indisputable positive impacts for society. The fact that we have been engaged in these endeavors since 1996 is evidence, we believe, of our company’s long-term financial sustainability.

We are proud of what we have accomplished, but we never take anything for granted – not our customers, collaborators, and partners, whose support has contributed to our growth and fueled many of our innovations, and certainly not our brilliant and dedicated employees, who share our vision of contributing to global health and a healthier planet. And always, we feel a deep commitment to our shareholders, many of whom have been with us from the beginning, whose enthusiasm, confidence, and trust propel us forward and inspire us to conduct our operations with the highest integrity.

These are the strategic priorities that form the foundation of our sustainability framework, based on the four primary pillars of Environment, Social, Human Capital, and Business Governance presented below:

According to Pharmaceutical Research and Manufacturers of America, the research and development costs of bringing a new drug to market are estimated between $1 and $2.6 billion, at an average time of 12-15 years. These costs are inevitably borne by individuals, place a heavy burden on society and can have a profound impact on global health. Simulations Plus was founded and built on the concept that by integrating the complex scientific processes involved in drug discovery, development and approval into simulation and modeling software applications, thereby simulating laboratory experiments in silico, we enable researchers and regulators to perform sophisticated analyses of complex drug behaviors in humans and animals. The use of simulation and modeling applications allows our customers the opportunity to reduce unnecessary animal testing and lowers the risks of exposure to humans in clinical trials. Our software and consulting solutions, that bridge machine learning, physiologically based pharmacokinetics (PBPK), quantitative systems pharmacology/toxicology (QSP/QST), and population pharmacokinetic/pharmacodynamic (PK/PD) modeling approaches, support the companies and regulatory agencies involved in these life-saving endeavors.

To read more about our work in this area please see our website PBPK Modeling and Simulation

Corporate Philanthropy & Academic Support
We believe corporate philanthropy and academic support are both a privilege and a responsibility. We are privileged to be in a position where we can provide donations of time, financial support, and scientific expertise to academic institutions, research institutes, and to students. Our sense of responsibility is based on a belief that supporting academia and research is vital to the advancement of science, leads to greater collaboration between the academic and private sectors, and will unquestionably benefit society and the world, at large.

Our support for the academic community is broad and deep. We provide academics worldwide with free reference site licenses for nonprofit research and teaching, including free access to our software in university instruction, and substantial discounts on our training courses and workshops. We also offer a 90% discount on our software to government agencies and non-profit organizations. In recent years, we have sponsored several students with awards given by the Society of Toxicology.

We provide sponsorships to numerous conferences, symposia, and associations such as the American Conference on Pharmacometrics (ACoP), American Association of Pharmaceutical Scientists (AAPS), American Chemical Society (ACS), Controlled Release Society (CRS), Groupe de Métabolisme et Pharmacocinétique (GMP), and the Gordon Research Conferences. Individually, many of our employees, including our division presidents and scientists at all levels, volunteer their time to teach and mentor at universities and professional organizations, and frequently serve as peer reviewers for scientific journals.

At the local level, we promote a culture of volunteerism, and we offer our employees the flexibility they need to participate, from sponsoring and participating in charity golf tournaments to volunteering to serve hot meals to the disadvantaged. In recent years, we have joined the global GivingTuesday movement and donated food, clothing, and financial support to several organizations that serve those in need in our communities.

Our commitment to community, to education, and to gender equity can best be summarized by how our Lancaster office has, for more than a decade, funded a summer scholarship to Tech Trek, a one-week residential science, technology, engineering and math (STEM) camp founded and operated by the American Association of University Women (AAUW) that is designed to inspire young women to attend college, to major in STEM fields, and to pursue STEM careers. Our own female scientists, who are excellent role models for these young women, have volunteered their time to personally present our Tech Trek scholarship each year.

Product Quality & Innovation
Quality Management System

As we continue to integrate the operations of our six business units, we have implemented a comprehensive cross-functional Quality Management System (QMS), with policies, procedures, training and controls that are consistent across all of SLP.

The QMS is comprised of policies, standard operating procedures (SOPs), and work instructions that define roles and responsibilities for each functional area. It provides uniform, permanent records of operational methods, software development techniques and validation, and other tasks relating to our business processes and procedures that support technologies in a regulated industry. We believe our QMS also serves as an important foundation for employee training.

The QMS team has operational responsibility for assessing software validation and compliance with various regulatory requirements. The QMS team is fully committed to a continuous improvement process and working with the entire organization to provide the best technology to our clients.

Innovation

As a technology company, we recognize that innovation is vitally important to achieving our objectives. We are continuously improving our products and services, and collaborations and partnerships with the pharmaceutical industry, universities, and government agencies – many fully funded – have resulted in some of our most advanced product features. Together with our focus on improving how scientists utilize knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents, and our expertise in integrating new and existing science from medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software, we are now among the leading solution providers of computational, or in silico, physiologically based pharmacokinetic (PBPK) modeling, physiologically based biopharmaceutics modeling (PBBM), and quantitative systems pharmacology/toxicology (QSP/QST) software and services.

Although we value all of our partnerships, it is a distinct privilege to have collaborated with several government agencies, including the U.S. Food and Drug Administration and the National Institutes of Health, on numerous projects. Some of these projects have been fully funded and others have involved research collaboration agreements (RCAs) and material transfer agreements (MTAs), and all have resulted in important advancements to our software applications as well as valuable contributions to their efforts in expediting and improving the drug approval process. In addition to these collaborations, we provide software licenses, training, and scientific expertise to these and other U.S. and international governmental regulatory and health agencies. We believe these collaborations have not only resulted in important innovations, they have served to validate our technology and to advance its acceptance by regulatory agencies and the pharmaceutical industry, worldwide. A partial list of our Partners and Collaborators is on our website.